TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06029023

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MTA Cement, propolis nano particle, curcumin nanoparticles
Description: MTA or nano propolis or nano curcumin will then be placed over the remaining healthy pulp per the manufacturer's recommendation. The cavities will be lined with glass ionomer cement and a permanent composite restoration will be placed after 6 months. After treatment, a periapical radiograph and CBCT will be immediately taken with ultra-low dose The patients and their parents will be interviewed by telephone on day 1 and day 7 post-surgery about any pain or adverse reactions related to the treatment. Paracetamol will be prescribed if the patients had pain, however, no antibiotic will be used following the surgery. The patients will receive a 3-month follow-up clinical and periapical radiographic examination, together with 6 months clinical and CBCT examinations.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MTA Cement, propolis nano particle, curcumin nanoparticles
Description: MTA or nano propolis or nano curcumin will then be placed over the remaining healthy pulp per the manufacturer's recommendation. The cavities will be lined with glass ionomer cement and a permanent composite restoration will be placed after 6 months. After treatment, a periapical radiograph and CBCT will be immediately taken with ultra-low dose The patients and their parents will be interviewed by telephone on day 1 and day 7 post-surgery about any pain or adverse reactions related to the treatment. Paracetamol will be prescribed if the patients had pain, however, no antibiotic will be used following the surgery. The patients will receive a 3-month follow-up clinical and periapical radiographic examination, together with 6 months clinical and CBCT examinations.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MTA Cement, propolis nano particle, curcumin nanoparticles
Description: MTA or nano propolis or nano curcumin will then be placed over the remaining healthy pulp per the manufacturer's recommendation. The cavities will be lined with glass ionomer cement and a permanent composite restoration will be placed after 6 months. After treatment, a periapical radiograph and CBCT will be immediately taken with ultra-low dose The patients and their parents will be interviewed by telephone on day 1 and day 7 post-surgery about any pain or adverse reactions related to the treatment. Paracetamol will be prescribed if the patients had pain, however, no antibiotic will be used following the surgery. The patients will receive a 3-month follow-up clinical and periapical radiographic examination, together with 6 months clinical and CBCT examinations.
Study: NCT06186921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.
Study: NCT04623749

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US
Description: Percutaneous Ultrasound guided FNAC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: Endoscopic Ultrasound guided FNAC
Study: NCT04865029

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo injection and placebo pill
Description: Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Cypionate 5 mg/ml
Description: Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 mg Oral Capsule
Description: Standard of Care along with Progesterone 200mg by mouth daily for 5 days starting at admission.
Study: NCT05201612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg, orally (po), twice a day (BID) continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg, intravenously (IV), every 21 days. Max 2 years (i.e. 35 cycles)
Study: NCT06234592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Standard care vasopressor therapy, norepinephrine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Standard care vasopressor therapy, norepinephrine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Standard care vasopressor therapy, norepinephrine infusion
Study: NCT04749095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sham subcutaneous infiltration
Description: bilateral ESP block will be injected with 20 ml of normal saline
Study: NCT05259163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LFR-260 portable phoropter
Description: Portable unit to evaluate visual refractive state of the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LFR-260 portable phoropter
Description: Portable unit to evaluate visual refractive state of the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional phoropter (SOC)
Description: Standard unit for evaluating visual refractive state of the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional phoropter (SOC)
Description: Standard unit for evaluating visual refractive state of the patient
Study: NCT05308290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure management according to cerebral autoregulation
Description: Intraoperative blood pressure will be targeted based on limits of cerebral autoregulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure management according to usual care
Description: Intraoperative blood pressure will be targeted based on usual care.
Study: NCT04999761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-115
Description: TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-115
Description: TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB122
Description: AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
Study: NCT05045274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: 1. Dapagliflozin: It will be given in a dose of 10 mg once daily within 24 hours after PPCI.~2. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~3. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~4. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.
Study: NCT00691795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine or fentanyl
Description: After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine or fentanyl
Description: After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
Study: NCT05765643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse parental support in symptom management using a mobile health App
Description: Parents in this group will receive a mobile App that includes health assessment, monitoring, health education and nurse support using phone calls over a 3-month period
Study: NCT05844059

Intervention type: OTHER
Intervention: Validated questionnaires
Description: BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS

Intervention type: OTHER
Intervention: Validated questionnaires
Description: BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
Study: NCT04999761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.
Study: NCT05741138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core strengthening
Description: Plank 1-3 sets of 10-15 reps per side at a slow tempo Side plank Draw in and lift, holding for 5 seconds with purposeful engagement of the core and leg musculature. Keep the head, shoulders, hips, knees and feet in a straight line.~Bridges - Lie supine with your knees bent and the feet flat on the floor. Lift your pelvis off the ground while supporting on your feet and shoulders. The bridge can be progressed by lifting one foot off the ground end extending the knee Leg rises - Lie on your back with your legs straight and your arms by your sides. Then lift one leg 4 inches of the ground. Your back has to stay flat on the floor. Don't allow it to arch. Alternate. The exercise can be progressed by lifting both legs at the same time.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Hot pack and TENS for 10 minutes (lumbar region and calf muscles) Ultrasound for 10 mins (lumbar region and calf muscles) Gentle passive stretching (calf muscles) Isometric exercises (lumbar region)
Study: NCT05914051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colloid preload
Description: 250 cc of colloid preload solution will be infused in the intervention group
Study: NCT04664101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)
Description: REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator
Description: Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
Study: NCT06553690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Gym Therapy
Description: Brain Gym Therapy is a structured program of physical movements designed to enhance cognitive function, reduce stress, and promote relaxation. The therapy is based on the principle that specific physical activities can stimulate brain function and improve overall mental and physical well-being.
Study: NCT05167422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trusted Messenger
Description: A nested waitlist design in which patients and staff are nested within two inpatient psychiatric units. New Hampshire Hospital staff will be trained to deliver the trusted messenger intervention up to 24 patients on the first unit while the second unit receives care as usual, during which time in-house vaccinations among patients on both units will be tracked in a registry. After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
Study: NCT05953168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Trastuzumab Deruxtecan for TNBC-LAR patients with HER2 low expression
Study: NCT05099432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CARMA technique
Description: Once standard polyp resection and assessment of the polypectomy site without magnification is completed, the CARMA technique will be applied. This will involve an assessment of the entire polypectomy margin using cap assisted magnification endoscopy with the ability to also use NBI (at the endoscopist's discretion) and documentation of any residual polyp noted.
Study: NCT04950595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based mince
Description: Spaghetti bolognaise meal made with plant-based mince

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef mince
Description: Spaghetti bolognaise meal made with beef mince
Study: NCT05630729

Intervention type: OTHER
Group type: OTHER
Intervention: My Kidney Guru
Description: My Kidney Guru is a program that will offer pediatric patients with CKD developmentally appropriate, interactive, and engaging instruction and practice opportunities to build knowledge and skills to manage CKD.
Study: NCT05714696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight discrimination experience
Description: In the experimental condition, participants will learn that their group members are biased against overweight people but not elderly or racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive negative feedback about their personal attributes by being labeled with negative weight-based stereotypes. Although some ratings will be positive (e.g., they will receive high ratings on being friendly and kind), participants will be rated poorly on attributes viewed as necessary to develop a strong marketing campaign (i.e., motivation to work hard, possessing self-discipline to persist at the task, and competence). After (ostensibly) assembling the group's preferences, the experimenter will inform participants that no one selected them to be their partner, thus they will perform the next few tasks alone. This manipulation has been shown to prompt feelings of social exclusion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control experience
Description: In the control condition, participants will learn that their group members have positive attitudes toward people with higher body weight, as well as elderly and racial/ethnic minority individuals, as indicated by the getting to know you summary ratings handout. Participants will also receive positive feedback about their personal attributes, as indicated by the summary ratings averaged across the three members. Finally, participants in the control condition will be told that one of their group members had to leave unexpectedly for a family emergency, so pairs cannot be assembled as usual, thus they will perform the next few tasks alone. This manipulation should not prompt feelings of social exclusion.
Study: NCT04519983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib Oral Tablet
Description: Aumolertinib 110 mg p.o. qd+ SRT(32Gy/4fx)
Study: NCT04794751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens
Description: senofilcon A C3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens
Description: senofilcon A C3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: delefilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: delefilcon A
Study: NCT05874362

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnosis of depressive episode or post traumatic stress disorder
Description: Clinical diagnosis of depressive episode or post traumatic stress disorder, confirmed

Intervention type: OTHER
Group type: OTHER
Intervention: No diagnosis of depressive episode or post traumatic stress disorder
Description: No elements in clinical assessment for the diagnosis of a depressive episode or post traumatic stress disorder
Study: NCT05293782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesitaping
Description: Kinesiotaping - muscle facilitation technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesitaping
Description: Kinesiotaping - muscle facilitation technique

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesitaping
Description: Kinesiotaping - muscle facilitation technique

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesitaping
Description: Kinesiotaping - muscle facilitation technique
Study: NCT05025592

Intervention type: DRUG
Intervention: Regorafenib
Description: patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not

Intervention type: DEVICE
Intervention: cTACE/DEB-TACE-HAIC
Description: conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion
Study: NCT05512351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.